Market open
QIAGEN/$QGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Ticker
$QGEN
Sector
Trading on
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
5,800
Website
QIAGEN Metrics
BasicAdvanced
$10B
110.06
$0.41
0.36
-
Price and volume
Market cap
$10B
Beta
0.36
52-week high
$47.93
52-week low
$39.03
Average daily volume
1M
Financial strength
Current ratio
2.175
Quick ratio
1.636
Long term debt to equity
38.657
Total debt to equity
57.024
Interest coverage (TTM)
10.46%
Management effectiveness
Return on assets (TTM)
4.89%
Return on equity (TTM)
2.57%
Valuation
Price to earnings (TTM)
110.058
Price to revenue (TTM)
5.119
Price to book
2.87
Price to tangible book (TTM)
14.23
Price to free cash flow (TTM)
21.9
Growth
Revenue change (TTM)
0.54%
Earnings per share change (TTM)
-80.93%
3-year revenue growth (CAGR)
-4.26%
3-year earnings per share growth (CAGR)
-32.78%
What the Analysts think about QIAGEN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for QIAGEN stock.
QIAGEN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
QIAGEN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
QIAGEN News
AllArticlesVideos
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million
Business Wire·2 weeks ago
QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase
Business Wire·2 weeks ago
QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $10B as of January 27, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 110.06 as of January 27, 2025.
Does QIAGEN stock pay dividends?
No, QIAGEN (QGEN) stock does not pay dividends to its shareholders as of January 27, 2025.
When is the next QIAGEN dividend payment date?
QIAGEN (QGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.